• NewAmsterdam Pharma raises $196m through Series A funding round pharmaceutical-technology
    January 18, 2021
    Clinical stage company NewAmsterdam Pharma (NAP) has raised $196m (€160m) through Series A funding round to support the full Phase III development of its ApoB and LDL-c lowering small molecule drug, obicetrapib.
  • MSD’s CETP inhibitor cuts heart risk by 9 percent pharmatimes
    August 31, 2017
    MSD has revealed that its CETP inhibitor anacetrapib reduced the risk of major coronary events by 9 percent versus placebo in patients with cardiovascular disease already taking LDL-C lowering therapy alongside atorvastatin.
PharmaSources Customer Service